-
BELIEVE spotlights quality and quantity approach to weight management with combo therapy
Steven B. Heymsfield, MD, and other panelists discussed how bimagrumab can preserve the weight reduction seen with semaglutide while also improving body composition.
-
CATALYST shows mifepristone for hypercortisolism in type 2 diabetes reduces A1C, weight
Vivian Fonseca, MD, and other investigators explained the results of the largest prospective study to date of hypercortisolism in difficult-to-treat diabetes and pharmacotherapy of hypercortisolism.
-
Add-on therapy improves glycemic outcomes and weight loss in adults living with type 1 diabetes and obesity
Researchers, including Viral N. Shah, MD, shared findings from phase 2 of the ADJUST-T1D study for the first time at the Scientific Sessions in Chicago. Once-weekly semaglutide enhanced the efficacy of automated insulin delivery alone in meeting time-in-range and weight-reduction targets.
-
Experts contrast heart and kidney diseases in type 1 and type 2 diabetes
Robert H. Eckel, MD, Silvio Litovsky, MD, and Anand Srivastava, MD, MPH, explored differences between type 1 and type 2 diabetes in respect to cardiovascular and kidney complications, then interpreted what this means for future research and ongoing clinical care.
-
Outstanding Scientific Achievement Award lecturer shares an unexpected journey into the field of diabetes by way of brown fat
Shingo Kajimura, PhD, explained how his curiosity about surviving cold Michigan winters led to the discovery that brown fat is a potent metabolic regulator that can control insulin and glucose levels independent of thermogenesis and independent of the canonical uncoupling protein 1 pathway.
-
Kelly West Award recipient combines data-driven knowledge with care
In her award lecture, epidemiologist Juliana C.N. Chan, MBChB, MD, FHKAM, FHKCP, FRCP, detailed her decades of data-driven research and her personal experience working with patients in a major metropolis transformed by global modernization.
-
QWINT signals paradigm shift for basal insulin dosing in type 2 diabetes
Chantal Mathieu, MD, PhD, and other investigators reported on findings from three QWINT studies. Efsitora alfa is now the second long-acting, once-weekly insulin analog that has been evaluated in robust phase 3 studies and proven to be non-inferior to daily insulins.
-
SOUL trial shows oral semaglutide has positive CV benefits in type 2 diabetes
Rodica Pop-Busui, MD, PhD, and other researchers shared new data showing oral semaglutide improved each of the composite measures of SOUL, death from cardiovascular causes, nonfatal stroke, and nonfatal myocardial infarction.
-
Panel examines benefits and barriers in therapies for CKD and diabetes
Katherine R. Tuttle, MD, discussed advancements in the treatment and management of diabetes and chronic kidney disease that have led to a transition from slowing disease progression to maintaining kidney health.
-
ADA President, Medicine & Science: Closing the circle from progress to promise is our unfinished journey
While the diabetes community has yet to reach the ultimate goal of improving health outcomes for every person living with diabetes, great strides have been made. Rita Rastogi Kalyani, MD, MHS, the ADA’s President, Medicine & Science, said the path forward needs to include professional education and advocacy.